Affiliation:
1. Seattle Genetics, Incorporated, 21823 30th Drive SE, Bothell, Washington 98021
Publisher
American Chemical Society (ACS)
Subject
Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology
Reference19 articles.
1. Antibody-Drug Conjugates for Cancer Therapy
2. Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
3. A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)
4. Krop, I. E., Beeram, M., Modi, S., Rabbee, N., Girish, S., Tibbitts, J., Holden, S. N., Lutzker, S. G., and Burris, H. A. (2007) A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer, In30th Annual San Antonio Breast Cancer Symposium,Abstract 310.
5. Younes, A., Forero-Torres, A., Bartlett, N., Leonard, J. P., Rege, B., Kennedy, D. A., Lorenz, J., and Sievers, E. L. (2007) A novel antibody-drug conjugate, SGN-35, (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma, preliminary results of a phase I tolerability study, In7th International Symposium on Hodgkin Lymphoma.
Cited by
144 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献